Limited proteolysis of cd2ap and progression of renal disease
AssigneesUniversity of Miami, Massachusetts General Hospital
InventorsJochen Reiser, Brian Adair
Life of this patent
Estimating the term…
Abstract
Compositions which specifically block cathepsin L function in podocytes, compositions which protect cytoskeletal adaptor protein (CD2AP) for degradation, compositions which modulate expression or function of cytoskeletal adaptor protein (CD2AP), protect against renal diseases or disorders. Methods of treatment in vivo involve use of one or more compositions.
Claims33
A method of treating renal diseases or disorders, comprising administering to a patient in need thereof, an effective amount of an agent which inhibits cytoskeletal adaptor protein (CD2AP) degradation and/or modulates expression or activity of CD2AP and/or modulates cathepsin-L expression or activity in vivo and,
- treating renal diseases or disorders.
A method of identifying agents which modulate cathepsin-L expression, function and/or activity in vivo comprising:
- culturing a kidney cell or kidney cell line;
- contacting said cells with one or more agents;
- measuring the cathepsin-L activity in podocytes;
- and,
- identifying agents which modulate the cathepsin-L expression, function and/or activity in vivo.
A method of identifying agents which modulate cytoskeletal adaptor protein (CD2AP) degradation, expression, function and/or activity comprising:
- culturing a kidney cell or kidney cell line;
- contacting said cells with one or more agents;
- measuring the cytoskeletal adaptor protein (CD2AP) degradation, expression, function, or activity;
- and,
- identifying agents which modulate cytoskeletal adaptor protein (CD2AP) degradation, expression, function and/or activity.
A cathepsin resistant cytoskeletal adaptor protein (CD2AP) molecule comprising a mutation at one or more amino acids in a cathepsin L cleavage site.
A composition comprising a pharmaceutical composition and/or one or more cathepsin L inhibitors and/or agents which inhibit cytoskeletal adaptor protein (CD2AP) degradation, in a therapeutically effective amount.
A composition comprising an agent which increases expression, function, and/or activity of cytoskeletal adaptor protein (CD2AP), in a therapeutically effective amount.
A vector expressing a cytoskeletal adaptor protein (CD2AP) cathepsin L resistant molecule.
A biomarker for the diagnosis of a disease or disorder characterized by proteinuria and/or identification of individuals at risk of developing a disease or disorder characterized by proteinuria comprising:
- cathepsin-L, dynamin, synaptopodin or cytoskeletal regulator protein synaptopodin, cytoskeletal adaptor protein (CD2AP), variants, mutants or fragments thereof.
An antibody or aptamer specific for CD2AP, mutants, variants, fragments, derivatives or analogs thereof.
Dependencies are inferred from the claim text.